Episomal Vector Hematopoietic Stem Cell Generation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a scarcity of functional hematopoietic stem cells (HSCs) for in vivo cellular replacement therapy and in vitro studies, with challenges in generating HSCs and hematopoietic stem and progenitor cells (HSPCs) from pluripotent stem cells that can engraft and sustain blood production in vivo.
Innovation Solution
A method involving the in vitro transfection of hemogenic endothelia cells with exogenous gene coding copies of transcription factors ERG, HOXA9, HOXA5, LCOR, and RUNX1, optionally including HOXA10 and SPI1, using a non-integrative vector to promote differentiation into multilineage HSCs and HSPCs that engraft well in recipients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If HSCs are generated from pluripotent stem cells through conventional differentiation methods, then HSCs can be produced in vitro, but the generated HSCs fail to engraft and sustain blood production in vivo
Solution Approach 1:
The patent applies preliminary action by introducing transcription factor genes (ERG, HOXA9, HOXA5, LCOR, RUNX1) into hemogenic endothelial cells before the endothelial-to-hematopoietic transition occurs. This pre-treatment with specific transcription factors prepares the cells with the necessary molecular machinery to successfully engraft and produce blood cells in vivo, addressing the failure of conventionally differentiated HSCs to establish functional engraftment.
2Reliability
If HSCs are obtained from bone marrow transplantation, then functional blood cell replacement is achieved, but the scarcity of HLA-matched HSCs limits transplantation availability
Solution Approach 1:
The patent enables self-service by generating patient-specific HSCs through differentiation of patient-derived pluripotent stem cells. This eliminates the need for HLA-matched donor HSCs, as each patient's own cells can be differentiated into functional HSCs that will engraft and produce blood cells, thereby providing unlimited availability of compatible transplant material.
3Stability of the object's composition
If transcription factors are introduced using integrative vectors, then gene expression is maintained, but insertional mutagenesis and safety concerns arise
Solution Approach 1:
The patent applies the extraction principle by removing the integrating vector system and replacing it with non-integrating viral vectors or mRNA transfection methods. This extracts the harmful integrative mechanism while preserving the beneficial gene expression function, allowing transcription factors to be delivered and expressed temporarily without permanent genomic integration, thereby eliminating insertional mutagenesis risks.
Data Source
AI summary
Embodiments herein relate to in vitro production methods of hematopoietic stem cell (HSC) and hematopoietic stem and progenitor cell (HSPC) that have long-term multilineage hematopoiesis potentials upon in vivo engraftment. The HSC and HSPCs are derived from pluripotent stem cells-derived hemogenic endothelia cells (HE) by non-integrative episomal vectors-based gene transfer.